"During the Q1 FY perio0d Cann Global through its Research Division, MCRG, invested approximately $1.1M towards the Research on MS being undertaken by the Technion Haifa, that following the earlier success in vitro in the lab, has now seen successful mice trials which are continuing, and trials on patients being monitored by leading Israeli hospitals are also currently underway."
Human trials of the strain that slows down MS have begun. That's fantastic news and has HUGE potential if successful!
Human trials mean is a strong indication the drug is having a positive effect.
- Forums
- ASX - By Stock
- CGB
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-2
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online